Caris Life Sciences, Inc. (CAI) Stock

About Caris Life Sciences, Inc.

Caris Life Sciences, Inc. (CAI) stock trades at $32.00 with a market capitalization of $9.05B. The stock is valued at a price-to-earnings (P/E) ratio of 81.72, price-to-book of 14.53, price-to-sales of 8.68. Over the past 52 weeks the stock has ranged between $14.19 and $33.66, and currently trades 4.9% below its 52-week high.

On profitability, Caris Life Sciences, Inc. generates a return on equity (ROE) of 18.77%, above the typical market range of roughly 12-15%, return on capital employed of 14.76%, an operating margin of 15.91%, a net profit margin of 10.62%.

Caris Life Sciences, Inc. by the numbers, 2015–2025

Between 2015 and 2025 Caris Life Sciences, Inc. reported revenue of $250.0M rising to $812.0M, a change of +224.8% across 10 years. Compounded, revenue has grown 14.3% a year over five years, 46.5% over three, 97.1% over the last twelve months. Net profit fell to $-538.0M.

Operating margin went from 27.3% in 2015 to 5.6% in 2025, a fall of 21.7 percentage points. The most recent net margin is 10.62%. On a trailing twelve-month basis to Jun '26, revenue is $990.0M and net profit $104.0M.

Borrowings fell from $1.4B to $379.0M, cash from operations was $83.0M in the latest year, positive in 7 of the last 10.

Return on equity has averaged -8.6% over five years, and was -93.2% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Caris Life Sciences, Inc. (CAI) — frequently asked questions